GlassScriptPhysician profile
Michelle Rene Burdette
NPI 1649274044
$8,592.10
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,717 · 2020: $1,608 · 2021: $2,132 · 2022: $2,136.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $963.38 | 2019-2022 | |
| Amarin Pharma, INC. | $763.93 | 2019-2022 | |
| Lilly USA, LLC | $639.84 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $626.44 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $610.51 | 2019-2022 | |
| Amgen INC. | $533.36 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.75 | 2019-2022 | |
| Abbvie INC. | $470.64 | 2020-2022 | |
| Pfizer INC. | $460.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $367.13 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.81 | 2019-2022 | |
| Allergan, INC. | $319.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $302.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $289.19 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $207.25 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $193.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $145.81 | 2019-2022 | |
| Horizon Therapeutics Plc | $139.12 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.03 | 2019 | |
| Sunovion Pharmaceuticals INC. | $86.96 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $68.67 | 2021 | |
| Akebia Therapeutics INC | $67.26 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $61.97 | 2019-2021 | |
| Genentech USA, INC. | $30.91 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $30.60 | 2020-2021 | |
| Astellas Pharma US INC | $26.78 | 2021 | |
| Ibsa Pharma INC. | $25.51 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.37 | 2021-2022 | |
| Mylan Specialty L.P. | $25.12 | 2022 | |
| Optinose US, INC. | $24.67 | 2021 | |
| Nevro Corp. | $24.17 | 2021 | |
| Dexcom, INC. | $20.35 | 2021 | |
| Shionogi INC | $18.44 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.65 | 2019 | |
| Esperion Therapeutics, INC. | $12.52 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Burdette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.